SCHEDULE 13G/A: RA Capital Management Reduces Stake in Kura Oncology Below 5% Threshold

RA Capital Management, along with its affiliates and key personnel, has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 4.9% in Kura Oncology, Inc., indicating a reduction below the 5% reporting threshold.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of 4,004,610 shares of Kura Oncology, Inc. Common Stock.
• This aggregate amount represents 4.9% of Kura Oncology's outstanding Common Stock.
• The percentage is based on 80,777,643 shares of Common Stock outstanding as of March 31, 2025, as reported in Kura Oncology's Definitive Proxy Statement on Schedule 14A filed on April 11, 2025.
• The Reporting Persons explicitly disclaim status as a "group" for purposes of this Schedule 13G.
• RA Capital Management, L.P. serves as the investment adviser for RA Capital Healthcare Fund, L.P., and Peter Kolchinsky and Rajeev Shah are controlling persons of RA Capital Management GP, LLC, the general partner of RA Capital Management, L.P.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership, not containing information that inherently indicates positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of institutional ownership changes within the biotechnology sector, indicating a passive investment position by RA Capital Management in Kura Oncology, Inc. It does not provide broader industry trends but reflects an investment firm's portfolio adjustments.

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor reducing its stake below the 5% threshold may influence investor perception and potentially share price, signaling a change in a major holder's position.

Key Dates

Keywords

Kura Oncology, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology, Healthcare Investment